Somewhat Positive Media Coverage Somewhat Unlikely to Affect Irhythm Technologies (NASDAQ:IRTC) Stock Price

News coverage about Irhythm Technologies (NASDAQ:IRTC) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Irhythm Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.2994223209 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of IRTC stock traded down $1.63 on Friday, hitting $60.37. The company’s stock had a trading volume of 155,308 shares, compared to its average volume of 162,615. The company has a current ratio of 5.72, a quick ratio of 5.64 and a debt-to-equity ratio of 0.41. Irhythm Technologies has a fifty-two week low of $32.10 and a fifty-two week high of $68.07. The firm has a market cap of $1,415.80, a PE ratio of -46.44 and a beta of 1.02.

Irhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.13). Irhythm Technologies had a negative net margin of 29.87% and a negative return on equity of 34.44%. The business had revenue of $28.20 million during the quarter, compared to analyst estimates of $26.79 million. During the same period in the previous year, the firm posted ($0.37) EPS. The firm’s revenue for the quarter was up 50.8% on a year-over-year basis. analysts forecast that Irhythm Technologies will post -1.54 EPS for the current fiscal year.

IRTC has been the topic of several research analyst reports. BidaskClub cut shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Zacks Investment Research cut shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine upgraded shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. JPMorgan Chase boosted their price target on shares of Irhythm Technologies from $62.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, BMO Capital Markets initiated coverage on shares of Irhythm Technologies in a report on Monday, March 5th. They set an “outperform” rating and a $76.00 price target on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $69.29.

In related news, EVP David A. Vort sold 935 shares of Irhythm Technologies stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $67.01, for a total value of $62,654.35. Following the completion of the sale, the executive vice president now owns 22,221 shares of the company’s stock, valued at approximately $1,489,029.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Vijay K. Lathi sold 169,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $62.41, for a total transaction of $10,547,290.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 352,452 shares of company stock valued at $22,613,610. 23.30% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at

Irhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Insider Buying and Selling by Quarter for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with's FREE daily email newsletter.

Leave a Reply